Arcutis Biotherapeutics, Inc. (ARQT) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Westlake Village, CA, United States. Le PDG actuel est Todd Franklin Watanabe.
ARQT a date d'introduction en bourse 2020-01-31, 342 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $3.05B.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company headquartered in Westlake Village, California, specializing in the development and commercialization of innovative treatments for dermatological diseases. The company's lead product candidate, ARQ-151, is a topical roflumilast cream that has completed Phase III clinical trials for plaque psoriasis and atopic dermatitis. Arcutis is advancing a robust pipeline that includes ARQ-154 for seborrheic dermatitis and scalp psoriasis, ARQ-252, a selective topical Janus kinase type 1 inhibitor for hand eczema and vitiligo, and ARQ-255, a deeper-penetrating topical formulation designed to treat alopecia areata. The company was incorporated in 2016 and rebranded as Arcutis Biotherapeutics in 2019.
